Resources
189 Results (showing 21 - 30)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 6/27/2022 (updated 3/27/2024)
Naloxone leave behind programs are a popular public health intervention for combatting the opioid epidemic. These programs are designed for first responders to educate and equip high risk, nonmedical individuals to respond to opioid overdose scenarios. However, stigma and misconceptions regarding naloxone remain common among medical providers, including emergency medical services (EMS) members.
Posted 7/6/2022 (updated 3/27/2024)
This paper illustrates survival models for analysis of trials of substance use treatment programs. It uses public release data from a study of extended-release naltrexone (XR-NTX), relative to buprenorphine-naloxone (BUP-NX).
Posted 4/20/2022 (updated 3/27/2024)
This updated TIP reviews what is known about treating the medical, psychiatric, and SUD-related problems associated with the use of cocaine and methamphetamine, as well as the misuse of prescription stimulants. The TIP offers recommendations on treatment approaches and maximizing treatment engagement and retention, and strategies for initiating and maintaining abstinence.
Posted 4/26/2022 (updated 3/27/2024)
Background: The US overdose crisis is driven by fentanyl, heroin, and prescription opioids. One evidence-based policy response has been to broaden naloxone distribution, but how much naloxone a community would need to reduce the incidence of fatal overdose is unclear. We aimed to estimate state-level US naloxone need in 2017 across three main naloxone access points (community-based programmes, provider prescription, and pharmacy-initiated distribution) and by dominant opioid epidemic type (fentanyl, heroin, and prescription opioid).
Posted 4/26/2022 (updated 3/27/2024)
Overview of the jail-based Medication Assisted Treatment program within the Adult Detention Center in Fairfax County, Virginia.
Posted 5/3/2022 (updated 3/27/2024)
Buprenorphine utilization is an effective treatment for opioid use disorder (OUD). Given the recent
increase in child maltreatment reports related to parental substance use, research should explore the correlation between buprenorphine treatment and child maltreatment–related outcomes.
Posted 7/25/2022 (updated 3/27/2024)
In 2019, the Addictions, Drug & Alcohol Institute (ADAI) at the University of Washington launched the “Meds First” program to provide onsite, low-barrier access to buprenorphine in partnership with six syringe services programs across WA State. A key component of the Meds First service model was the addition of care navigation to support client engagement and retention in OUD treatment.
Posted 9/28/2023 (updated 3/27/2024)
The University of Vermont Center on Rural Addiction (UVM CORA), the University of Rochester, and the Fletcher Group have conducted an online survey assessing SUD stigma (including stigmatizing language), treatment needs and barriers, and concerns through the perspectives of rural, RCORP-affiliated practitioners. The data report explores the findings of the survey, including practitioner recommendations on improving access to OUD treatment.
Posted 10/12/2023 (updated 3/27/2024)
Posted 7/25/2022 (updated 3/27/2024)
In New York City (NYC), there were 2062 overdose fatalities in 2020, the deadliest year on record for NYC and the US. Fentanyl and its analogs were the most common substances involved in overdose deaths in NYC, present in 77% of such deaths in 2020. A characteristic of fentanyl-involved overdose is rapid onset of overdose symptoms; however, with timely administration of oxygen or naloxone, deaths can be averted.